Sep 6 2012
ImmuNext, Inc., today announced that it has entered into an agreement
with Janssen Biotech, Inc., focused on the development of novel
therapeutics that modulate the immune system for the treatment of cancer.
Under the terms of the agreement, ImmuNext will grant Janssen a
worldwide, exclusive license to develop and commercialize therapeutics
that antagonize the V-region immunoglobulin-containing suppressor of
T-cell activation (VISTA) signaling pathway. VISTA is a newly identified
negative checkpoint regulator.
Potential payments to ImmuNext under the agreement include an upfront
payment, plus payments for reaching certain development and
commercial-based milestones, which could total more than $150 million.
ImmuNext is also eligible to receive royalties on sales of products and
sponsored research support.
ImmuNext and Janssen will engage in a collaborative effort to carry out
research and development of cancer therapeutics that antagonize the
VISTA signaling pathway. Janssen will be responsible for clinical
development and commercialization of all products under the agreement.
"VISTA is an exciting, novel, negative checkpoint regulator that we
anticipate will be a key target for enhancing immunity to solid and
liquid cancers," stated Randolph Noelle, Ph.D, ImmuNext's chief
scientific officer.
"We look forward to working with Janssen, a global leader in the field
of oncology, to develop innovative immunotherapies to improve the lives
of cancer patients," commented David DeLucia, ImmuNext's chief executive
officer.
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis